ArticleBritish journal of pharmacology2006
Sphingosine-1-phosphate and sphingosylphosphorylcholine: two of a kind?
Article in British journal of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 12 citations in OpenAlex.
- Article
- Sphingosylphosphorylcholine activates dendritic cells, stimulating the production of interleukin-12.Immunology · 2007Article
- Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine.Naunyn-Schmiedeberg's archives of pharmacology · 2006Article
- Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine.Naunyn-Schmiedeberg's archives of pharmacology · 2006Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingosine-1-phosphate and sphingosylphosphorylcholine are structurally related signalling molecules. Although they share some biological effects, it is debated whether this involves the same receptors. In this issue, Mathieson and Nixon report that these two lipids activate the same transcription factor but do so via distinct signalling pathways. Against this background, we discuss some of the potential pitfalls in studies comparing the effects of the two sphingolipids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.